Episode 26: Bigger Models Won't Save Biomanufacturing

We sit down with Shawn Manchester, CEO of TripleBar, whose path from yeast DNA repair to metabolic engineering at MIT to biomanufacturing AI gave him a front-row seat to one of biotech's most underappreciated problems. Everyone funds discovery. Nobody funds manufacturing. And yet a molecule that can't be made reliably and cheaply at scale never reaches a patient. Shawn makes the case that biomanufacturing is where the real bottleneck lives, and why it's finally getting the AI attention it deserves. It's a refreshingly grounded conversation about what biological AI actually requires to work.